Tandutinib

DB05465

small molecule investigational

Deskripsi

MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.

Struktur Molekul 2D

Berat 562.703
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

394 Data
Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Tandutinib.
Propacetamol The serum concentration of Propacetamol can be increased when it is combined with Tandutinib.
Leuprolide The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Sulfisoxazole.
Amitriptyline The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Nimodipine.
Promazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Droperidol.
Imipramine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Imipramine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Chlorpromazine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Tandutinib.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Papaverine.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Chlorpheniramine.
Nifedipine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Clarithromycin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Levacetylmethadol.
Saquinavir The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Saquinavir.
Clomipramine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Clomipramine.
Mibefradil The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Aceprometazine.
Terlipressin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Antazoline.
Crizotinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Crizotinib.
Bedaquiline The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Eperisone.
Butriptyline The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Butriptyline.
Ceritinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ceritinib.
Lenvatinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Lenvatinib.
Melperone The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Melperone.
Benidipine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Benidipine.
Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dexchlorpheniramine maleate.
Amifampridine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Amifampridine.
Mocetinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Mocetinostat.
Entinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Entinostat.
Gilteritinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Gilteritinib.
CUDC-101 The risk or severity of QTc prolongation can be increased when Tandutinib is combined with CUDC-101.
Simendan The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Simendan.
Ricolinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Ricolinostat.
Mizolastine The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Mizolastine.
Abexinostat The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Abexinostat.
Oxatomide The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Oxatomide.
Sitafloxacin The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Sitafloxacin.
Sultopride The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Sultopride.
Otilonium The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Otilonium.

Target Protein

Receptor-type tyrosine-protein kinase FLT3 FLT3
Platelet-derived growth factor D PDGFD

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16902153
    DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 1;108(12):3674-81. Epub 2006 Aug 10.
  • PMID: 16715961
    Kiyoi H: The present status of, and problems with the development of FLT3 kinase inhibitors. Rinsho Ketsueki. 2006 Apr;47(4):270-7.
  • PMID: 16447713
    Kiyoi H: Possibility of targeting FLT3 kinase for the treatment of leukemia. Rinsho Ketsueki. 2005 Mar;46(3):187-97.
  • PMID: 15242881
    Griswold IJ, Shen LJ, La Rosee P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW: Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8. Epub 2004 Jul 8.
  • PMID: 18185521
    Brownlow N, Vaid M, Dibb NJ: Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia. 2008 Jul;22(7):1452-3. doi: 10.1038/sj.leu.2405085. Epub 2008 Jan 10.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul